The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.

On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion ...

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...

The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 study titled ‘A Phase 3 Randomized, ...

Sjögren's Syndrome News CARRA 2025 Rituximab, Cyclophosphamide Combo Safe in Pediatric Patients Although the study was conducted at a single center, patients achieved clinical improvement and ...

Patients with Sjögren syndrome have an increased risk for non-Hodgkin lymphoma. It is estimated that approximately 10% of patients with significant dry eye disease have Sjögren syndrome.

Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome. JAMA, 2014; 312 (3): 249 DOI: 10.1001/jama.2014.7682 ...